Big endothelin-1 (big ET-1) is converted to 21-amino acid residue endothelin-1 (ET-1) via a specific cleavage at Trp 21 -Val 22 by endothelin converting enzyme (ECE). This conversion is an essential step to produce bioactive ET-1 and represents a regulatory site in the biosynthesis of this potent vasoconstrictor. ECE-1a, a unique membrane-bound enzyme, processes big ET-1 more efficiently than other big ET isoforms, which mainly differ in the C-terminal tail (residues 22-38). In this study, each of the highly conserved residues, Val , and Gly 34 were replaced with Ala in the preproendothelin-1 (PPET-1) cDNA using site-directed mutagenesis. The mutant and wild-type cDNAs were transiently transfected into Chinese hamster ovary cells along with ECE-1a cDNAs, and concentrations of the resulting recombinant peptides, ET-1 and big ET-1, in the transfection media were then measured. of big ET-1 were substituted with the corresponding residues in big ET-2 and big ET-3. These findings suggest that the C-terminal tail has an important role in the intracellular processing of big ET-1 by ECE-1a. Herein we also report that a recombinant big ET-1 analog we previously generated and characterized, (Ala 21 )big ET-1, inhibits ECE-1a activity in a dose-dependent (K i =1 µM) and competitive manner.
1 more efficiently than other big ET isoforms, which mainly differ in the C-terminal tail (residues 22-38). In this study, each of the highly conserved residues, Val , and Gly 34 were replaced with Ala in the preproendothelin-1 (PPET-1) cDNA using site-directed mutagenesis. The mutant and wild-type cDNAs were transiently transfected into Chinese hamster ovary cells along with ECE-1a cDNAs, and concentrations of the resulting recombinant peptides, ET-1 and big ET-1, in the transfection media were then measured. The concentration of immunoreactive ET-1 in the media from Val 22 , Pro 25 , Pro 30 , Gly 32 , and Leu 33 mutant PPET-1-transfected cells was 4-to 6-fold lower than that of wild type and (Gly 34 <Ala)PPET-1. Moreover, with the exception of Gly 34 , there was a corresponding increase in the concentrations of immunoreactive big ET-1 in the media from mutants. Similar results were obtained when His 27 , Val 28 , and Ser 35 of big ET-1 were substituted with the corresponding residues in big ET-2 and big ET-3. These findings suggest that the C-terminal tail has an important role in the intracellular processing of big ET-1 by ECE-1a. Herein we also report that a recombinant big ET-1 analog we previously generated and characterized, (Ala 21 )big ET-1, inhibits ECE-1a activity in a dose-dependent (K i =1 µM) and competitive manner.
INTRODUCTION
Endothelin-1 (ET-1), the most potent vasoconstrictor known at present, is generated from posttranslational processing of its 212-amino acid residue precursor, preproendothelin-1 (PPET-1), in multiple enzymatic steps (Yanagisawa et al. 1988 ). PPET-1, which contains the signal sequence in the first 17 amino acid residues, is processed to big ET-1 by dibasic-specific endopeptidases and a carboxypeptidase. The final step in the biosynthesis of ET-1 involves the selective hydrolysis of the Trp 21 -Val 22 bond of the 39-amino acid residue peptide, big ET-1, by endothelin converting enzyme (ECE) (Yanagisawa et al. 1988) . As big ET-1 is less potent than ET-1 (Kimura et al. 1989) , the conversion of big ET-1 to ET-1 is believed to be essential for physiological activity. Therefore, ECE inhibitors that prevent the formation of active ET-1 are potential candidates for therapeutic intervention.
Two distinct genes encoding ECE have recently been cloned (Shimada et al. 1994 , Xu et al. 1994 , Emoto & Yanagisawa 1995 and designated as ECE-1 (Xu et al. 1994) and ECE-2 (Emoto & Yanagisawa 1995) . Both gene products are membrane-bound proteases that contain a zincbinding motif and show sequence similarity to neutral endopeptidase-24·11 and KELL protein. ECE-1 and ECE-2 are 71% and 52% identical to each other within the C-terminal one-third of the extracellular domain and N-terminal region, respectively (Emoto & Yanagisawa 1995) . ECE-2, which has an acidic pH optimum, is localized mainly in the lysosomes (Emoto & Yanagisawa 1995) . The localization of ECE-1 has been very controversial, and it has recently been reported that there are two ECE-1 isoforms that are generated from the same gene by alternative splicing: ECE-1a and ECE-1b (Turner & Murphy 1996) . Bovine ECE-1a has been reported to be primarily intracellular, whereas ECE-1b is found on the plasma membrane (Emoto et al. 1996) . The neutral pH optimum and wide tissue distribution of ECE-1 mRNA suggest that ECE-1 isoforms are the physiologically relevant enzymes for the cleavage of big ET-1 (Turner & Murphy 1996) .
Interestingly, the purified ECE-1 isoforms process big ET-1 more efficiently than big ET-2 and cleave big ET-3 very poorly (Xu et al. 1994) . As the most variable residues in the big ET isoforms are located in the C-terminal region between residues 27 and 38, it is reasonable to conclude that these residues are important for recognition and cleavage by ECE-1, in addition to the Trp 21 -Val 22 cleavage site. We have previously shown that, when a mutant PPET-1 cDNA, (Trp 21 <Ala)PPET-1, was expressed in COS-7 cells, both the processing and secretion of the recombinant (Ala 21 )big ET-1 was impaired . Thus transient expression of PPET-1 cDNA in mammalian cells provided additional information on the structural determinants for the intracellular processing events leading to secretion of bioactive ET-1 that cannot be obtained by use of synthetic big ET-1 analogs.
In an attempt to define the role of the C-terminal tail region of big ET-1 in the biosynthesis, recognition and cleavage by ECE, the highly conserved residues, , and Ser 35 contribute to the specificity of ECE-1 for big ET-1, these amino acids were individually changed to Gln, Thr, and Asn respectively, which are the corresponding residues in big ET-2 and big ET-3. Our results show that, with the exception of Gly 34 <Ala, these replacements resulted in a decrease in the conversion of big ET-1 to ET-1 by ECE-1. Moreover, recombinant (Ala 21 )big ET-1 inhibited ECE-1a activity in a dose-dependent manner.
MATERIALS AND METHODS

Reagents
The cDNAs for bovine ECE-1a and human PPET-1 were kindly provided by Dr Masashi Yanagisawa (The University of Texas Southwestern Medical Center, Dallas, TX, USA) and Dr Carla Zoja (Mario Negri Institute for Pharmacological Research, Bergamo, Italy), respectively. Cell culture media and serum were purchased from Fisher Scientific (Pittsburg, PA, USA). Phosphoramidon, phenylmethylsulfonyl fluoride (PMSF), ethylenediaminotetra-acetic acid (EDTA), polyoxyethylene-10-lauryl ether, p-chloromercuriphenylsulfonic acid, and trypsin were from Sigma Chemical Co. (St Louis, MO, USA). ET-1 and big ET-1 enzyme-linked immunoassay (ELISA) kits and synthetic big ET-1 were products of American Research Products (Belmont, MA, USA) and Peninsula Laboratories (Belmont, CA, USA) respectively. Pfu DNA polymerase was obtained from Stratagene Cloning Systems (La Jolla, CA, USA).
Preparation of PPET-1 mutants
PPET-1 mutants were generated using the QuickChange Site-Directed Mutagenesis protocol (Stratagene Cloning System). Briefly, the desired mutations were introduced into the pcDNA3/ PPET-1 construct via two mutant primers, each complementary to opposite strands of the vector, in a polymerase chain reaction performed with Pfu DNA polymerase. The PCR product was then digested with Dpn I, which cleaves the methylated, wild-type parental strands. The remaining strands were then transformed into DH 5 cells and mutant clones were identified by sequencing and restriction digestion mapping. The amino acid sequence comparison of big ET-1 isoforms and the replacements made are described in Fig. 1 .
Cell culture and transient expression of mutant PPET-1 cDNAs
Chinese hamster ovary cells (CHO-K1), obtained from American Type Culture Collection (Rockville, MD, USA), were grown as recommended. Cells  1. The amino acid sequence comparison of big ET-1 isoforms and the list of mutations described in the current study. The residues that differ in big ET-1 are shown in bold and the mutated residues are indicated as bold and italics. The arrow indicates the cleavage site.
between passage numbers 3 to 6 were used for transfections. To eliminate the ECE-1-like activities present in tissue-culture-grade trypsin preparations, a highly purified crystallized trypsin (Sigma, T7418) was employed in tissue culture procedures.
The CHO cells were transiently co-transfected with the eukaryotic expression vector pcDNA3/ PPET-1, wild type and mutants, and pcDNA3/ ECE-1a by incubating the cells with Lipofectamine-DNA mixture for 5 h at 37 C. For a 75-cm 2 tissue culture flask, 1 µg wild-type or mutant PPET and 10 µg ECE-1a DNA were used. As controls, cells were also individually transfected with pcDNA3 vector (mock-transfection), pcDNA3/ PPET-1, or pcDNA3/ECE-1a constructs. After transfection, the cells were incubated in growth medium supplemented with 10% (v/v) fetal bovine serum for 18 h, and then the serum concentration was reduced to 2%. After 48 h, the medium was collected and cell extracts were prepared for subsequent ET-1 and big ET-1 ELISA analysis. Both preparations were stored at 80 C until the day of analysis.
Cell extracts were prepared by rinsing the cells with Buffer A (150 mM NaCl, 20 mM HEPES, pH 7·4, 1 mM PMSF, 5 mM EDTA) and then scraping them on ice into 1 ml Buffer A containing 1% Nonidet P-40 and 20% glycerol. The cells were then homogenized at 400 r.p.m. for 2 min with a Tekmar tissumizer and incubated on ice for 30 min to solubilize the membrane bound proteins. The homogenate was centrifuged at 15 000 g for 30 min and the supernatant was assayed for the presence of ET-1 and big ET-1-like immunoreactivity.
(Ala 21 )big ET-1 recombinant peptide was prepared and characterized as described previously .
ELISA of ET-1 and big ET-1
The concentrations of immunoreactive (ir) ET-1 and irbig ET-1 in the transfection media and cell extracts were measured using ELISA kits specific for ET-1 and big ET-1. In these assays, an immunoaffinity-purified polyclonal capture antibody and a monoclonal detection antibody, both highly specific for the peptide being measured, ET-1 or big ET-1, were used to provide maximum sensitivity (Ergul et al. 1996) . The sensitivity of the ET-1 assay was 0·1-50 fmol/ml, and the crossreactivities of the antibodies used were reported to be <1% with big ET-1 (1-38) and the C-terminal fragment (22-38), and <5% with big ET-2. The sensitivity of the big ET-1 assay was similar and ranged between 0·1 and 70 fmol/ml. The crossreactivity of the assay with both ET-1 and the C-terminal fragment (22-38) was <1%. Samples were diluted with the assay buffer to be in the range of standards and were analyzed three times in separate ELISA runs.
Preparation of soluble membranes
Forty-eight hours after transfection with ECE-1a cDNA as described above, approximately 10 8 cells were rinsed with cold phosphate-buffered saline, scraped off the flasks and collected by centrifugation. All subsequent procedures were performed at 4 C. Cells, resuspended in 10 volume of Buffer A (20 mM Tris-HCl, pH 7·4, 20 µM pepstatin A, 1 mM PMSF, and 250 mM sucrose), were homogenized at 400 r.p.m. with a Tekmar tissumizer. The homogenate was then centrifuged at 1000 g for 10 min, and the resulting supernatant was centrifuged at 100 000 g for 60 min. The crude membrane fraction (pellet) was solubilized in buffer A containing 2·5% polyoxyethylene-10-lauryl ether for 30 min. The mixture was then centrifuged at 50 000 g for 60 min, and the supernatant was stored as solubilized membrane.
Measurement of ECE-1 activity
In order to determine whether (Ala 21 )big ET-1 has any inhibitory effect on ECE-1 activity, enzyme activity was measured by incubating various concentrations of big ET-1 (0·01-2 µM) with 30 µg of solubilized membrane preparation in 50-µl reaction mixtures in a 0·1 M sodium phosphate buffer, pH 6·8, containing 0·5 M NaCl for 1 h at 37 C in the presence and absence of 1·5 µM (Ala 21 )big ET-1 recombinant peptide. In addition, to compare the inhibitory effects of the recombinant peptide and phosphoramidon, 30 µg membrane protein was incubated with 0·1 µM big ET-1 in the absence and presence of various concentrations of (Ala 21 )big ET-1 (0·1-2 µM) and phosphoramidon (0·1-100 µM). The reaction was terminated with 50 µl 5 mM EDTA and the mixture assayed for ET-1 by ELISA in three individual runs. Reaction conditions were set for the hydrolysis to be in the linear range with respect to time and protein concentration.
ET-1 (mean ...) were calculated as described (Kendall & Stuart 1977) . The values obtained for wild type recombinant peptides were compared with those of mutants using unpaired Student's t-test and a P value <0·05 was considered significant.
RESULTS
In order to clarify the roles of highly conserved amino acid residues in the C-terminal tail of big ET-1, and of the residues that differ among the big ET-1 isoforms, on enzyme activity and specificity of ECE-1a, several PPET-1 mutant cDNAs were constructed ( Fig. 1) and transiently transfected into CHO cells along with the ECE-1a cDNA. There was no detectable irET-1 or irbig ET-1 in the medium from mock-transfected cells, confirming that CHO cells do not produce ET-1 (Xu et al. 1994) . In cells transfected with the PPET-1 cDNA alone, only irbig ET-1 was detected, suggesting that these cells are devoid of ECE-1 activity.
As shown in Fig. 2 , almost all the mutations introduced into the PPET-1 cDNA interfered with the processing of the big ET-1 to ET-1. The ratio of ET-1 to big ET-1 in the medium obtained from cells co-transfected with cDNAs to wild type PPET-1 and ECE-1 was 4 1. This ratio was about 3 for the Gly 34 <Ala and His 27 /Val 28 <Gln/Thr mutants and in the range 0·2-0·6 for the other mutants (Table 1) . These results also indicated that the replacement of proline residues by alanine led to a decrease in the amount of ET-1 and big ET-1 secreted into the medium. The total amount of recombinant protein in the medium (sum of irET-1 and big ET-1) of cells transfected with Pro 25 <Ala and Pro 30 <Ala mutants was significantly less (P<0·05) than that of those detected in the media of cells transfected with wild type and other mutants (Table 1) . In order to determine whether these mutations interfere with the secretion of the peptides, extracts of cells were also assayed for Pro 25 <Ala and Pro 30 <Ala mutants, but there was no detectable irET-1 and big ET-1 (data not shown). Furthermore, to investigate whether co-transfection affects the transfection efficiency and if the enzyme activity is similar in all cases, solubilized membrane fractions were prepared from a single transfection with the ECE-1a cDNA or several co-transfections with wild type, Pro 25 <Ala, His 27 <Gln, Leu 33 <Ala, and Ser 35 <Asn PPET-1 cDNAs, and their associated ECE-1a activities measured. The respective values obtained were 14·5 0·2, 12·3 0·2, 11·4 0·5, 10·0 0·3, 11·2 0·4, and 12·6 0·1 pmol/mg protein.h. These results indicate that co-transfection does not reduce the transfection efficiency.
We have previously shown that COS-7 cells, unlike CHO cells, have endogenous ECE-like activity and when Trp 21 was replaced with Ala in the PPET-1 cDNA and transiently expressed, the recombinant peptide (Ala 21 )big ET-1 accumulated in the cells, suggesting that this replacement interferes with both the secretion of big ET-1 and  2. Production of ET-1 and big ET-1 by transiently transfected CHO cells. Cells were co-transfected with cDNAs for PPET-1, wild type or mutants, and ECE-1a as described in Materials and Methods; after 48 h, the medium was collected and assayed by ELISA kits specific for ET-1 and big ET-1. Data are given as means ... (n=4).  1. Amount of total (irET-1+irbig ET-1) and the ratio (irET-1:irbig ET-1) of recombinant proteins in the media after transient co-transfection of CHO cells with wild-type and mutant PPET-1 and ECE-1a cDNAs irET-1+irbig ET-1 (fmol/ml) its cleavage by ECE . To investigate the possibility that the (Ala 21 )big ET-1, accumulating in the cells, interacts with the converting enzyme ECE, co-transfection experiments with wild-type PPET-1 and (Trp 21 < Ala)PPET-1 cDNAs were performed. Single transfections with only wild-type or (Trp 21 < Ala)PPET-1 cDNA were also repeated under the same conditions, and irET-1 and irbig ET-1 concentrations were measured. To be consistent with our previous results, constructs in the pSVL expression vector and COS-7 cells were used for this set of transfections. In the medium collected from cells co-transfected with wild-type and (Trp 21 [sA]la)PPET-1 cDNA, there was a decrease in irET-1 concentrations accompanied by a corresponding increase in irbig ET-1 concentrations as compared with that obtained from cells transfected with wild-type PPET-1 cDNA alone (Table 2) . This observation strongly suggests that (Ala 21 )big ET-1 interacts with ECE and prevents the processing of wild-type big ET-1.
In order to characterize further the interaction between ECE-1a and (Ala 21 )big ET-1, enzyme assays were performed using the soluble membrane fractions prepared from CHO cells transfected with the ECE-1a cDNA and (Ala 21 )big ET-1 obtained from extracts of COS-7 cells transfected with this mutant PPET-1 cDNA . Irbig ET-1 in the extracts was characterized by a radioimmunoassay and HPLC as described previously . Initially, 30 µg soluble membrane incubated with 0·1 µM synthetic big ET-1 in the absence and presence of various concentrations of (Ala 21 )big ET-1 (0·01-2 µM) and the nonspecific metalloprotease inhibitor, phosphoramidon (0·1-100 µM). The K i value obtained for (Ala 21 )big ET-1 (0·9 µM) was similar to that of phosphoramidon (0·6 µM) (Fig. 3) . In order to ensure that these findings were specific for ECE-1a and (Ala 21 )big ET-1, a series of control experiments was performed. Because the recombinant (Ala 21 )big ET-1 was obtained from crude extracts of cells transfected with (Trp 21 Ala)PPET-1 cDNA, cell extracts and medium obtained from wild-type PPET-1 cDNA-transfected cells were also assayed as controls, to eliminate the possibility that any inhibitory effect detected is nonspecific. As shown in Fig. 3 , these preparations had no effect on enzyme activity. Although intact COS-7 cells exhibit ECE-like activity, there was no enzyme activity associated with the cell extracts. This finding was most probably a result of the loss of the activity during the preparation and concentration of the extracts.
Next, to characterize the inhibitory properties of (Ala 21 )big ET-1, the enzyme assays were repeated in the presence and absence of 1·5 µM (Ala 21 )big )big ET-1, phosphoramidon, and medium containing recombinant wild type ET-1. Thirty micrograms membrane protein and 0·1 µM big ET-1 were incubated in the absence and presence of various concentrations of inhibitors and the ET-1 produced was measured. The data obtained in the presence of inhibitors were normalized to those obtained in the absence of inhibitors and expressed as the % inhibition of enzyme activity. The results represent means ... of three individual experiments.
ET-1 and various concentrations of synthetic big ET-1 (0·01-2 µM), to determine the K m and V max values. In the presence of the inhibitor, the ECE-1a activity, as measured by ET-1 produced, was significantly reduced (Fig. 4A) . As shown in Fig.  4B , the double-reciprocal analysis of the same data showed that the change in K m was quite subtle, from 0·23 0·06 µM to 0·53 0·33 µM in the absence and presence of the inhibitor respectively. However, the V max value was reduced fivefold, indicating that (Ala 21 )big ET-1 behaves as a competitive inhibitor. To clarify whether (Ala 21 )big ET-1 acts as a partial substrate and contributes to the ECE-1 activity shown in Fig. 4A , the enzyme assays were performed using the recombinant protein as a substrate. As shown in Fig. 4A , even at the greatest concentration of the substrate (2 µM), the conversion to ET-1 was less than 8% of that of synthetic big ET-1.
DISCUSSION
The results described herein show that the C-terminal tail of big ET-1 is important in the recognition and cleavage by ECE-1 and that a big ET-1 analog, (Ala 21 )big ET-1, behaves as a potent ECE-1a inhibitor and only a weak substrate.
Reports on ECE purified from various tissues or cell lines revealed distinctive properties of its specificity. Recently, human ECE-1 has been reported to cleave another vasoregulatory peptide, bradykinin, with a K m value of 978 µM, whereas its affinity for big ET-1 under the same conditions was 8 µM (Hoang & Turner 1997) . Although one cannot rule out the possibility that ECE-1 might have a broader spectrum of substrates, thus far big ET isoforms appear to be the only biological substrate for this enzyme (Turner & Murphy 1996 , Turner & Tanzawa 1997 . Moreover, even the conversions of big ET isoforms to ET display marked differences, depending upon the sources from which the ECEs are purified. For instance, a partially purified preparation from EA.hy926 cells processed human big ET-1 much more efficiently than big ET-2 and failed to convert big ET-3 (Waxman et al. 1994) . Similarly, the cloned and expressed recombinant enzymes cleaved big ET-1 more efficiently than big ET-2 and had almost no effect on big ET-3 (Schmidt et al. 1994 , Shimada et al. 1994 . However, the bovine endothelial ECE-1a cDNA, which was the ECE cDNA used in the present study, processed both big ET-2 and big ET-3 with lower velocities of hydrolysis than that of big ET-1 (Xu et al. 1994 ). These observations suggest that big ET-1 possesses unique structural elements required for recognition and cleavage by ECE-1. Our results, showing reduced conversion efficiencies after replacements of the highly conserved amino acid residues with Ala, and also of the residues unique to big ET-1 with the corresponding residues in big ET-2 and big ET-3, provide further support that the C-terminal tail of the big ET-1 molecule is involved in the recognition, cleavage, or both, by ECE-1.
Previously, it was reported that the minimal substrate for ECE was the sequence from Ile 19 to Gly 34 of big ET-1, and that truncated big ET-1 analogs have substantially greater specific activity, thus indicating that the N-terminal loop structure of big ET-1 (residues 1-15) hinders the conversion (Okada et al. 1991 (Okada et al. , 1993 . Alanine scanning of a synthetic truncated big [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , and Gly 34 were more important than the other residues in the C-terminal tail of big ET-1 (Okada et al. 1993) . Our results are in good agreement with these studies. Using the full-length mutant big ET-1 analogs expressed in a mammalian expression system, we showed that Recently, a molecular model for big ET-1 was reported in which the structure of the endothelin core was almost identical to the crystal structure of ET-1 (Peto et al. 1996) . In their big ET-1 structure (Fig. 5) , the C-terminal helix is extended and, because of a loop formed by a hydrogen bond between Asp 18 and Thr 24 , the chain folds back on itself, resulting in hydrogen bonds between residues 1 and 5 of the N-terminal region of big ET-1 and residues 27 and 29 of the C-terminal tail. The structure is further compacted by a turn generated by hydrogen bonding between Ser 35 and Ser 38 bringing the side chain of Ser 38 in close contact with Lys 9 . As a previous study (Corder 1996) reported that the conversion rate of big ET-1 analogs, in which Lys 9 residue was chemically modified, was substantially reduced, it was argued that this residue forms a hydrogen bond with Ser 38 and stabilizes the big ET-1 structure (Peto et al. 1996) . In the present study, the replacement of Ser 35 with Asn, which is the corresponding residue in big ET-2 and big ET-3, affected the cleavage and resulted in lower ET-1 production. This finding supports the molecular modeling studies predicting a bond between Ser 35 and Ser 38 . Interestingly, we previously demonstrated that, when (Lys 9 < Glu)PPET-1 and (Lys 9 <Ala)PPET-1 cDNAs were transiently expressed in COS-7 cells, the conversion of mutant big ET-1 analogs to ET-1 was similar to that of wild type, suggesting that these mutations did not interfere with the processing by ECE . These findings, however, were different from those obtained with Lys 9 -modified big ET-1 analogs (Corder 1996) . One possible explanation of this difference might be that functional groups incorporated into Lys 9 are quite bulky and disrupt the bond between Ser 38 and Lys 9 , whereas Ala or Glu substitution did not affect the compact structure of big ET-1.
Interestingly, on the basis of the results obtained by two groups, who showed that the replacement of Val 22 with Phe enhanced the cleavage substantially (Ohnaka et al. 1993) and that the substitution of Trp 21 with Phe or Tyr did not alter the processing in Xenopus oocytes (Fabbrini et al. 1993) , it was suggested that there was no strict requirement for Trp-Val at the cleavage site (Turner & Murphy 1996) . It was also proposed that a possible requirement for substrate binding and catalysis by ECE-1 might be a large hydrophobic residue in the S 1 (i.e. Val
22
) site and a rather flexible S 1 position (i.e. Trp 21 ) (Hoang & Turner 1997) . However, we previously demonstrated that when the (Trp 21 < Ala)PPET-1 mutant cDNA was expressed in COS-7 cells, which possess endogenous ECE activity, (Ala 21 )big ET-1 accumulated in the cells, suggesting that this mutation interfered with both the processing and the secretion of the recombinant peptide . In this study, we showed that co-transfection of wild-type PPET-1 with (Trp 21 <Ala)PPET-1 resulted in a reduction in the formation of wild-type ET-1 from big ET-1, providing further support for an inhibitory role of (Ala 21 )big ET-1 on ECE. Moreover, enzyme activity studies performed using soluble membrane preparations of ECE-1a and big ET-1 in the presence and absence of (Ala 21 )big ET-1 demonstrated that, at the concentrations used (1-2 µM), (Ala 21 )big ET-1 acts as a potent competitive inhibitor and only a weak substrate of ECE-1a. Interestingly, a big ET-1 analog, ]big ET-1(16-38) (Morita et al. 1994) , has been reported to have inhibitory effects on the converting enzyme, demonstrating the importance of this region of the molecule in recognition by ECE.
Our cell culture expression system also provided information on the contribution of the individual residues on the synthesis of the recombinant peptides. For example, (Pro 25 <Ala)PPET-1 and  5. The ribbon diagram of the molecular model of big ET-1 (modified from Peto et al. 1996) . The proposed hydrogen bonds in the structure are indicated by the dashed lines.
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Journal of Molecular Endocrinology (1998) 21, 307-315 (Pro 30 <Ala)PPET-1 cDNAs expressed at lower levels than the wild-type and other mutant PPET-1 cDNAs. Possible explanations of this finding are at least twofold: (i) as proline residues are important for introducing turns into the proteins, Ala replacement might cause misfolding of the protein leading to faster degradation, or (ii) the mutations might have interfered with the recognition of anti-big ET-1 antibodies used in the ELISA experiments, resulting in low irbig ET-1 concentrations. Although we do not have direct evidence, we believe the former is more likely, because the irET-1 concentrations in the media obtained from cells transfected with Pro mutants were also lower than those of the wild type and other mutants. In addition, crossreactivity of the anti-big ET-1 antibody with ET-1 and C-terminal fragment, (22-38)big ET-1, were reported to be <1%, indicating that it recognizes a certain conformation of big ET-1 molecule and even a failure of recognition by the antibody would imply a conformational change.
In conclusion, the data presented herein strongly suggest that the amino acid residues between positions 21 and 35 contribute to the recognition and cleavage of big ET-1 by ECE-1a and that (Ala 21 )big ET-1 is a potent inhibitor and only a very weak substrate for ECE-1a. Although the replacement of the residues unique to big ET-1 by the corresponding residues in big ET-2 and big ET-3 reduced the conversion rate of these mutant big ET-1 analogs, detailed enzyme assays are required to determine whether these residues, His 27 , Val 28 , and Ser
35
, confer the high specificity of ECE-1a for big ET-1.
